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instruments: BD FACSCanto II flow cytometer, P/ACE MDQ System (Beckman Coulter, USA), Uncoated fused silica capillary (Postnova Analytics GmbH, Germany)\
software: UnScan-It (<https://www.silkscientific.com>), SnapGene version 4.1 (htt://[www.snapgene.com](http://www.snapgene.com){#intref0015}), STATISTICA (StatSoft, Krakow, Poland).Data formatprocessed data, analyzed dataParameters for data collectionCytotoxicity tests: Levels of lactate dehydrogenase (LDH) in culture media were measured after 48 hours from treatment with investigated proteins.\
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Cell chemotaxis assay: 46BR.1 N fibroblasts and HaCaT keratinocytes were cultured in silicone culture inserts in the presence of AGF_30 and AGF_40. Migratory response was measured after 24 hours.\
*In vitro* immunogenicity assay: PBMCs were incubated with the AGF_30 and AGF_40 concatemeric proteins for 48 h. After incubation, cells were stained with monoclonal, fluorochrome-labelled antibodies (anti-CD3, CD4, CD8, CD16, CD56, CD25, CD69, CD71, HLA-DR) and analyzed using a flow cytometer. Flow cytometry was performed in order to measure the level of activation in immune cell subpopulations.\
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1. Data description {#sec1}
===================

We reported a method for efficient amplification of DNA fragments as linked in head-to-tail polymers, leading to the production of multiple copies of the desired peptide/peptides \[[@bib1]\]. The data presented in this article demonstrate sequences of DNA primers and recombinant constructs used/obtained in the course of amplification, for the HBV epitope fragment and AGF-derived fragments. Data concerning selected biochemical properties and biological activity of the AGF-derived concatemeric proteins are also presented.

[Fig. 1](#fig1){ref-type="fig"} shows a series of synthetic, amplifying DNA modules. The modules contain convergent recognition sequences for *Sap*I - a Type IIS restriction endonuclease (Rease), separated by a short DNA segment. The segment can contain an ancillary restriction site for *Sma*I for an alternative route of insert DNA cloning. Variants differ in terms of their possibility to manipulate three reading frames (which may be highly useful when amplifying natural, non-synthetic DNA sequences), as well as the presence or absence of a His6 tag. The amplifying modules may be re-cloned into various classes of DNA vectors, containing alternative origins of replication, antibiotic resistance genes, transcriptional promoters or translation signals. Following the amplification module, there are three stop codons in three reading frames. Genetic maps and DNA sequences of the constructed DNA amplification-expression vectors: pAMP1_A, pMAP1_B, pAMP1_C, pAMP1_HisA, pAMP1_HisB, pAMP1_HisC, pET28AMP-HisA are provided in Supplementary material in the GenBank file format. The pAMP vectors were designed on the basis of p15A origin vector pACYC184 and pRZ4737. Thus, pACYC184 and pRZ4737 maps and DNA sequences are also included in Supplementary material.Fig. 1**A series of 6 modules designed for directional amplification of a DNA fragment maintaining ORF continuity.** The modules contain convergent recognition sequences for *Sap*I - a Type IIS REase, separated by a short DNA segment. This segment can contain an ancillary restriction site for *Sma*I to provide an alternative route of insert DNA cloning. The variants differ in their possibility of manipulating three reading frames (which may be highly useful when amplifying natural, non-synthetic DNA sequences), as well as the presence or absence of a His6 tag. Variant D was used for the amplification of an epitope from the surface antigen S of HBV. The amplifying modules may be re-cloned into various classes of DNA vectors, containing alternative origins of replication, antibiotic resistance genes, transcriptional promoters or translation signals. Following the amplification module, there are three stop codons in three reading frames.Fig. 1

[Fig. 2](#fig2){ref-type="fig"} and [Fig. 3](#fig3){ref-type="fig"} show DNA sequences of amplification cassettes with introduced alternations, enabling the purification and identification of the resulting polypeptides, such as secretion signals, tags or fusion proteins. The amplification cassette for fusion with ubiquitin is presented in [Fig. 2](#fig2){ref-type="fig"}. Both genetic map and sequence of the dedicated DNA vector pETAMP_SapI-Ubq are provided in Supplementary material in the GenBank file format. The amplification/secretion PhoA and MalE modules for secretion of the obtained recombinant concatemeric protein into the periplasmic space are presented in [Fig. 3](#fig3){ref-type="fig"}. Genetic maps and sequences of the dedicated DNA vectors: pETAMP_MalE and pET28AMP_PhoA are provided in Supplementary material in the GenBank file format.Fig. 2**Diagram showing the amplification cassette for N-terminal fusion of the poly-protein with ubiquitin.** Panel A. A schematic representation of the designed module. Panel B. Nucleotide and aa sequences of the amplification/expression cassette along with the selected functional areas which contain DNA fragments encoding: His6 tag, c-Myc tag, WYY motif and ubiquitin. The WYY motif was introduced to allow a direct A280 concentration measurement of the concatemeric protein.Fig. 2Fig. 3**Nucleotide and aa sequences of the amplification/secretion modules along with the selected functional areas which contain DNA fragments encoding: His6-tag and *E. coli* secretion signals.** The designed modules enable secretion of the obtained recombinant concatemeric protein into the periplasmic space. Panel A. PhoA amplification module. Panel B. MalE amplification module.Fig. 3

[Fig. 4](#fig4){ref-type="fig"} shows a diagram presenting the construction of the recombinant pAMP1-HisA_HBVepitope plasmid. The plasmid was constructed to assess the developed DNA fragment amplification technology \[[@bib1]\]. A synthetic DNA fragment encoding a 7-aa epitope from the S protein of HBV was cloned into the *Sma*I restriction site of the amplification/expression vector pAMP1-HisA \[[Fig. 4](#fig4){ref-type="fig"}\]. The resulted recombinant plasmid pAMP1_HisA_HBVep_1 can be cleaved with *Sap*I to excise the modified DNA gene encoding the epitope. Then, the excised DNA fragment can be subjected to autoligation *in vitro*, yielding a series of DNA segments of increasing length, that are directional concatemers (polymers) of the epitope gene, as it was described by Skowron et al., 2020 \[[@bib1]\]. The obtained concatemers can be re-cloned into the amplification-expression vector and subjected to another amplification cycle. The aa sequences of the poly-HBV epitopic proteins, obtained using this approach \[[@bib1]\]: TKPTDGNGP_10, TKPTDGNGP_13, TKPTDGNGP_15, TKPTDGNGP_20, TKPTDGNGP_30 are included in Supplementary materials in FASTA format. The detailed maps and DNA sequences of the corresponding recombinant DNA constructs are also provided in the GenBank file format: pAMP1_HisA_HBVep_1, pAMP1_HisA_HBVep_10, pAMP1_HisA_HBVep_13, pAMP1_HisA_HBVep_15, pAMP1_HisA_HBVep_20, pAMP1_HisA_HBVep_30.Fig. 4**Diagram showing the construction of the recombinant pAMP1-HisA_HBVepitope plasmid.** A synthetic, phosphorylated, 21-bp DNA fragment (encoding the 7 aa epitope of HBV) was cloned into the *Sma*I restriction site of the amplification/expression vector pAMP1-HisA ([Fig. 1](#fig1){ref-type="fig"}D). The resulted recombinant plasmid can be cleaved with *Sap*I to excise the modified DNA gene encoding the epitope. Then, the excised DNA fragment can be subjected to *in vitro* autoligation, yielding a series of DNA segments of increasing length, which are directional concatemers (polymers) of the epitope gene. The obtained concatemers can be re-cloned into the amplification-expression vector and subjected to another amplification cycle. Alternatively, the obtained recombinant genes can be expressed in *E. coli* and the resulting poly-epitopic protein variants purified.Fig. 4

[Fig. 5](#fig5){ref-type="fig"} shows an example of a synthetic, concatemeric gene, encoding the 25-mer HBV epitope. DNA sequence of the gene was optimized for expression in *Escherichia coli* (*E. coli*). Such a synthetic gene (the longest concatemeric DNA oligomer, obtainable by chemical synthesis), encoding the desired number of copies of the epitope, can be cloned into the *Sap*I-linearized DNA amplification/expression vector as initial DNA 'monomer'. The proposed alternative amplification approach may allow to obtain longer DNA concatemers in a shorter time \[[@bib1]\]. The map and DNA sequence of the recombinant pAMP1_HisA_HBVep_25_opt, encoding the 25-mer HBV epitope is provided in Supplementary materials in the GenBank file format. The aa sequences of the obtained proteins poly-HBV epitopic proteins: TKPTDGNGP_opt_25, TKPTDGNGP_opt_50, TKPTDGNGP_opt_100, TKPTDGNGP_opt_150, TKPTDGNGP_opt_200, TKPTDGNGP_opt_450 \[[@bib1]\] are included in Supplementary materials in FASTA format. The detailed maps and DNA sequences of the corresponding recombinant DNA constructs are also provided in Supplementary material in the GenBank file format: pAMP1_HisA_HBVep_25_opt, pAMP1_HisA_HBVep_50_opt, pAMP1_HisA_HBVep_100_opt, pAMP1_HisA_HBVep_150_opt, pAMP1_HisA_HBVep_200_opt, pAMP1_HisA_HBVep_450_opt.Fig. 5**DNA and aa sequences of the designed 25-mer of the 7-aa HBV epitope.** The DNA gene sequence was optimized for expression in *E. coli*. The gene was chemically synthetized, cloned into the *Sap*I-cleaved pAMP1-HisA vector and subjected to the amplification process.Fig. 5

The obtained recombinant DNA constructs, encoding various numbers of the HBV epitope, were used to transform *E. coli* BL21 Star (DE3) for concatemeric gene expression. Detailed protocols for purification of the poly-HBV epitope protein variants are presented in the Methods section of this article.

After the methods layout was established, DNA sequences encoding peptides of varying length, derived from the angiopoietin-related growth factor (AGF) were designed. The pET28AMP_MalE DNA vector \[Supplementary material\], enabling secretion of polyepitopic protein to the periplasmic space, was selected for cloning of genes encoding the AGF derivatives. DNA sequences of designed genes were optimized for expression in *E. coli*. An example of a designed gene coding for the 10-mer of the AGF-derived peptide is shown in [Fig. 6](#fig6){ref-type="fig"}. The aa sequences of the obtained AGF-derived proteins \[[@bib1]\]: AGF_10, AGF_20, AGF_30 AGF_40 are provided in Supplementary materials in FASTA format. The detailed maps and DNA sequences of the corresponding recombinant DNA constructs are provided in the GenBank file format: pET28AMP_MalE_AGF10, pET28AMP_MalE_AGF20, pET28AMP_MalE_AGF30, pET28AMP_MalE_AGF40.Fig. 6**Nucleotide and aa sequences of the designed 10-mer of the AGF-derived peptide.** The DNA gene sequence was optimized for expression in *E. coli*. The gene was *de novo* synthetized and cloned into the *Eco*RV site of the pUCmini DNA vector. *Sap*I DNA recognition sequences are shown in blue. Nucleotides derived from pUCmini are marked in gray. *Sap*I cleavage results in the formation of 3-nt, single-stranded 5′ sticky ends. Apart from the amplification function, in the final concatemeric protein, these ends (shown in red) are responsible for the addition of a proline residue, the so-called "helical breaker", which separates epitope monomers and facilitates independent folding of the epitope into tertiary structures, thereby helping to maintain their natural spatial structure.Fig. 6

[Fig. 7](#fig7){ref-type="fig"} shows effectiveness of the exemplary autoligation reactions. The effectiveness of the reactions was determined by densitometric analysis of polyacrylamide gels, resulting from electrophoretic analysis of the DNA autoligation products, obtained in the first and second round of amplification of the model 7-aa HBV epitope \[1, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}A\]. The raw data corresponding to [Fig. 7](#fig7){ref-type="fig"} are provided in Supplementary materials.Fig. 7**Formation efficiency of DNA concatemers coding for the 7 aa HBV epitopes.** Panel A. Autoligation efficiency of the monomeric DNA substrate, encoding the 7 aa HBV epitope. Panel B. Autoligation efficiency of the pentameric DNA substrate, encoding five repeats of the 7 aa HBV epitope. The intensity of the DNA band corresponds to the monomer or pentamer measured using UnScan-It software; percentage of the non-ligated DNA substrate was calculated for each tested ligation time. Autoligation experiments were performed in triplicate. Panel C. Densitometric analysis of DNA bands corresponding to monomeric (see [Fig. 3](#fig3){ref-type="fig"}A, Skowron et al., 2020 \[[@bib1]\]) and pentameric (see [Fig. 4](#fig4){ref-type="fig"}A, Skowron et al., 2020 \[[@bib1]\]) DNA substrates.Fig. 7

[Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}, [Fig. 10](#fig10){ref-type="fig"}, [Fig. 11](#fig11){ref-type="fig"} show biological effects of the AGF-derived concatemeric proteins on human skin keratinocytes and fibroblasts. The cytotoxicity of the 30-mer and 40-mer of the AGF-derived peptide (AGF_30 and AGF_40, respectively) \[[Fig. 8](#fig8){ref-type="fig"}\], as well as, their influence on cell migration \[[Fig. 9](#fig9){ref-type="fig"}\], their immunogenicity \[[Fig. 10](#fig10){ref-type="fig"}\], and their allergenic potential \[[Fig. 11](#fig11){ref-type="fig"}\] were established as descried by Skowron et al., 2020 \[[@bib1]\]. The raw data corresponding to [Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}, [Fig. 10](#fig10){ref-type="fig"}, [Fig. 11](#fig11){ref-type="fig"} are provided in Supplementary materials.Fig. 8**Cytotoxicity of the protein variants AGF_30 (TSRGDHELLGGAAPVGG_30) and AGF_40 (TSRGDHELLGGAAPVGG_40) towards 46BR.1N fibroblasts and HaCaT keratinocytes.** Results are presented as the mean ± SEM. All results come from four independent experiments performed in quadruple. \*p \< 0.05 relative to control (C), U-Whithey Test. T-additional positive control, cells treated with Triton X100 (1.0%) - maximum LDH release (maximum cytotoxicity).Fig. 8Fig. 9**Effects of AGF-derived poly-protein variants on cell migration.** Panel A. The migratory response of human 46BR.1 N fibroblasts and HaCaT keratinocytes to the AGF_40 poly-protein after 24 h of incubation. Panel B. Effect of the AGF-derived poly-proteins on chemotactic migration of the human keratinocyte cell line (HaCaT) after 24 h of incubation. The final protein concentration was 1 μg/ml. All results were obtained from four independent experiments performed in quadruple and presented as mean ± SEM. \*p \< 0.05 relative to control, U-Whithey Test.Fig. 9Fig. 10**Immunogenicity of the AGF-derived poly-proteins.** The *in vitro* immunogenicity assay was performed on human PBMCs exposed to the AGF-derived polyprotein variants AGF_30 (TSRGDHELLGGAAPVGG_30) and AGF_40 (TSRGDHELLGGAAPVGG_40) for 48 h. The final protein concentration was 1.0 μg/ml. The analysis was performed with flow cytometry in order to evaluate the activation level of selected immune cell subpopulations. The chart presents the overall activation percentage of selected lymphocytes/leukocytes: CTL - T cytotoxic lymphocytes, Th -- T helper cells, NK- natural killer cells. Results were obtained from four independent experiments performed and are presented as medians with min = max. p -- value was evaluated with the Mann-Whitney *U* Test (in comparison to positive control). Untreated cells constituted a negative control, whereas cells stimulated with LPS (1 μg/ml, lipopolysaccharide) and PHA (2.5 μg/ml, phytohemagglutinin) were a positive control.Fig. 10Fig. 11***In vitro* activation of basophils in the presence of activating antibodies (first positive control), fMLP (second positive control), the AGF_30 protein, the AGF_40 protein (1 μg/ml) and negative control.** Results are presented as a single data (% of activated basophils for each patient) and median.Fig. 11

[Fig. 12](#fig12){ref-type="fig"} shows stability of AGF_30 in human plasma. The protein stability was measured with capillary electrophoresis (CE) as descried by Skowron et al., 2020 \[[@bib1]\]. Half-life (t 1/2 = 3.5 h) was established, based on the change in area noted for the AGF_30 peak. The raw data are provided in Supplementary materials.Fig. 12**The AGF_30 protein stability in human plasma.** Panel A. Capillary electrophoresis (CE) analysis of AGF stability in human plasma. Panel B. Stability profile of AGF_30 based on the obtained CE data. Separation conditions: uncoated fused silica capillary of 40 cm (30 to detector) × 75 μm; background electrolyte (BGE): 25 mM phosphate (pH 7.0), 50 mM SDS; separation at 20 kV; temperature 25 °C; hydrodynamic injection at 0.5 psi for 8 s; normal polarization; detection at 214 nm. The AGF_30 peak is marked with an asterisk. Incubation time of AGF_30 with human plasma is shown.Fig. 12

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Oligonucleotides {#sec2.1}
---------------------

*Primers for p15Aori-PR vector construction:*PR-Sac-MCS5′-CCCGAGCTCATATGGTCCATGGTCATGAACAACCTCCTTAGTACATGCAACCA-3′PR-Cla5′-GAAATCGATCGCGATCTTGCTCAATTGTTATCAGCTATG-3′FpACYC-Sac5′-GGCGCGAGCTCGACCCGGTCGAATTTGCTTTCGAATTTCTG-3′RpACYC-ClaI5′-GAATCTTCATCGATGGCATGCTGTCAAACATGAGAATTACAACT-3′*Primers for site-specific mutagenesis of pET21a(+) and pET28a(+)*Fpet28adelsap5′-CGTAAGGAGAAAATACCGCATCAGGCGCTCCTCCGCTTCCTCGCTCACTGACTCGCTG-3′Rpet28adelSap5′-CAGCGAGTCAGTGAGCGAGGAAGCGGAGGAGCGCCTGATGCGGTATTTTCTCCTTACG-3′Fpet28adelsma5′-GATATTCTTCTAATACCTGGAATGCTGTTTTaCCGGGGATCGCAGTGGTGAGTAACCATGCATC-3′Rpet28adelsma5′- GATGCATGGTTACTCACCACTGCGATCCCCGGtAAAACAGCATTCCAGGTATTAGAAGAATATC-3′*Primers for amplification of the insert from pAMP1-HisA recombinant constructs*Fnest35′-CGTGCGTGTTGACTATTTTACCTC-3′Rnest25′-CCCTTAAACGCCTGGTGCTACG-3′

2.2. A detailed purification procedure of the HBV-derived polyepitopic protein variants {#sec2.2}
---------------------------------------------------------------------------------------

### 2.2.1. Resulting from the first and second amplification round {#sec2.2.1}

The purification scheme included the following stages:1.*Sonication and heat treatment.* 1 L of bacterial culture was centrifuged (5000×*g*, 15 min). The bacterial pellet was resuspended in 30 ml of sonication buffer \[50 mM Tris-HCl, pH 8.8 at 10 °C, 5 mM EDTA pH 8.0, 50 mM NaCl, 0.02% Triton X-100, 5 mM 2-mercaptoethanol (βMe), 1 × protease inhibitor solution (the Sigma FAST™ Protease Inhibitor), 0.5 mg/ml chicken egg lysozyme\] and sonicated (8 × 30 s, 23 kHz, 3 μm). The lysate was centrifuged, and the supernatant was incubated at 70 °C for 30 min. Denatured thermolabile *E. coli* proteins were removed by centrifugation.2.*Polyethyleneimine (PEI) treatment.* 10% PEI was gradually added to the supernatant to a concentration of 0.4%. After stirring for 30 min at 4 °C, the suspension was centrifuged.3.*Ammonium sulphate (AmS) fractionation.* The resulting supernatant was subjected to two-step fractionation at 4 °C. At first, AmS was added to a final concentration of 30%. The suspension was incubated with stirring for 12 h and then centrifuged. During the second step, 50% saturation was applied, the suspension was incubated with stirring for 3 h and centrifuged. The resulting protein pellet was subjected to further purification steps.4.*CM-Sepharose chromatography.* Cation exchange chromatography was conducted in buffer A \[NaH~2~PO~4~/NaHPO~4~ pH 6.0 at 10 °C\] using a 1 ml CM-Sepharose ion exchange column and an automated Akta Pure chromatography system (GE Healthcare, Uppsala, Sweden), with a NaCl concentration gradient (0.7--1.1 M in buffer A).5.*IMAC chromatography.* For IMAC purification, a 1 ml HiTrap® IMAC Fast Flow column (GE Healthcare) and the Akta Pure chromatography system were used. The protein sample was loaded onto the equilibrated Ni Sepharose resin (equilibration buffer: 20 mM Tris-HCl pH 8.0 at 10 °C, 0.5 M NaCl, 5 mM imidazole).Then, the resin was washed with 5 column volumes (CV) of equilibration buffer. Additional washing was performed with 5 CV of washing buffer (20 mM Tris-HCl pH 8.0 at 10 °C, 0.5 M NaCl, 20 mM imidazole). Proteins were stepwise eluted with 6 CV of elution buffer (20 mM Tris-HCl pH 8.0 at 10 °C, 0.5 M NaCl, 250 mM imidazole).6.*Resource S chromatography.* Cation exchange chromatography was conducted in buffer A \[20 mM Tris-HCl pH 6.0\] using a 6 ml Resource S ion exchange column and the Akta Pure chromatography system, with a NaCl concentration gradient (0.7--0.9 M in the buffer A).7.*Size exclusion* chromatography (SEC). SEC was performed using an Akta Pure chromatography system and HiLoad 16/600 Superdex 200 PG column, in buffer S \[20 mM Tris-HCl pH 8.0 at 10 °C, 100 mM NaCl, 0.1 mM EDTA\]. The purified protein preparations were concentrated, dialysed against PBS buffer and lyophilized.

### 2.2.2. Resulting from the alternative amplification round {#sec2.2.2}

The purification scheme included the following stages:1.*Sonication and heat treatment.* Performed as described in a).2.*PEI treatment.* Performed as described in a).3.*AmS fractionation.* Performed as described in a), except that 60--70% AmS saturation was applied.4.*IMAC chromatography.* For IMAC purification, a 5 ml HiTrap® IMAC Fast Flow column (GE Healthcare) and the Akta Pure chromatography system were used. The protein sample was loaded onto the equilibrated Ni Sepharose resin (equilibration buffer: 20 mM Na/PO~4~, 500 mM NaCl, pH 7.4 at 10 °C).Then, the resin was washed with 5 column volumes (CV) of equilibration buffer. Proteins were eluted with imidazole gradient (0--500 mM the equilibration buffer).5.*Resource Q chromatography (used as a negative step).* Anion exchange chromatography was conducted in buffer Q \[20 mM Tris-HCl, 0.1 mM EDTA, pH 9.0 at 10 °C\] using a 6 ml Resource Q ion exchange column and the Akta Pure chromatography system. The protein sample was loaded onto the equilibrated resin. Then, the resin was washed with 10 CV of equilibration buffer. In the buffer conditions applied, the polyepitopic proteins did not bind to the resin and eluted from the column in the wash fraction. Purified protein preparations were concentrated and subjected to SEC.6.*SEC* chromatography. SEC was performed using an Akta Pure chromatography system and HiLoad 16/600 Superdex 200 PG column, in buffer S \[20 mM Tris-HCl pH 8.0 at 10 °C, 100 mM NaCl, 0.1 mM EDTA\]. Purified protein preparations were concentrated, dialysed against PBS buffer and lyophilized.

2.3. A detailed purification procedure of the AGF-derived poly-protein variants {#sec2.3}
-------------------------------------------------------------------------------

The purification scheme of the AGF-derived poly-protein variants from *E. coli* BL21(DE3)\* cells included the following stages:1.*Lysis.* In order to extract periplasmically secreted proteins, the bacterial cell pellet was resuspended in 100 ml of sucrose buffer \[20% sucrose, 5 mM EDTA\]. After 30 min incubation at room temperature (RT), the cells were centrifuged, and the resulting cell debris was resuspended in 60 ml of pre-cooled 10 mM MgCl~2~. After 10 min incubation on ice, the lysate was centrifuged.2.*AmS fractionation.* The resulting supernatant was subjected to two-step fractionation at 4 °C. At first, AmS was added to a final concentration of 30%. The suspension was incubated for 1 h with stirring, and then centrifuged. During the second step, 60% saturation was applied, the suspension was incubated with stirring for 1 h and centrifuged. The resulting protein pellet was subjected to further purification steps.3.*IMAC chromatography.* The pellet was resuspended in 110 ml of buffer A \[50 mM NaH~2~PO~4~, 500 mM NaCl\] and filtered. Chromatography was performed in buffer A using a 5 ml HiTrap® IMAC Fast Flow column (GE Healthcare) and the Akta Pure chromatography system (GE Healthcare, Uppsala, Sweden), with an imidazole concentration gradient (10--500 mM in the buffer A). Chromatographic fractions containing the AGF-derived protein variant were collected and dialyzed against 1x PBS buffer at 4 °C.4.*Affinity based lipopolysaccharide (LPS) removal.* Endotoxin removal was performed in accordance with the manufacturer\'s instructions. 20 ml of the protein sample was transferred into the equilibrated Proteus NoEndo M spin column and centrifuged for 30 min at 100×*g*. The resulting, purified protein preparation was free of LPS.

2.4. LC--MS--MS/MS analysis {#sec2.4}
---------------------------

Selected homogenous protein variants were subjected to liquid chromatography coupled to tandem mass spectrometry (LC--MS--MS/MS) \[[@bib2]\]. LC-MS-MS/MS analysis were performed in a Mass Spectrometry Laboratory (IBB PAS, Warsaw). Gel slices containing the protein variant were subjected to a standard 'in-gel digestion' procedure. Any protein disulphide bonds were reduced with 100 mM DTT (30 min at 56 °C), alkylated with iodoacetamide (45 min; in a darkroom; room temperature) and digested overnight with trypsin (sequencing Grade Modified Trypsin, Promega). The resulting peptides were eluted from the gel with 0.1% trifluoroacetic acid (TFA) and 2% acetonitrile (ACN) and measured by LC/MS. HPLC separation parameters: precolumn: RP-18 (nanoACQUITY Symmetry R ® C18,Waters), 0.1% TFA as a mobile phase. Nano-HPLC: RP-18 column (nanoACQUITY BEH C18, Waters), flow rate 250 nl/min, gradient: 0--35% B in 70 min, solvent A: 0.05% formic acid in water, solvent B: 0.05% formic acid in ACN. The column outlet was directly coupled to the ion source of the spectrometer working in the regime of data dependent MS to MS/MS switch (Orbitrap Velos mass spectrometer-Thermo Electron Corp.). Raw data were processed using Mascot Distiller followed by Mascot Search (Matrix Science, UK) against the predicted protein-derived reference peptide masses. Search parameters selected for LC--MS--MS/MS for the precursor and product ions mass tolerance were as follows: 20 ppm and 0.1 Da, respectively. Trypsin specificity allowed for one missed cleavage site. Fixed modification selected for the search: cysteine by carbamidomethylation. Variable modification selected for the search: oxidation of methionine. Peptides with a Mascot Score exceeding the 5% False Positive Rate threshold and with a Mascot Score exceeding 30 were positively identified.

2.5. Western blotting and immunodetection procedure {#sec2.5}
---------------------------------------------------

The purified protein variants were separated by SDS-PAGE in 15% Tris-Glycine gels and electroblotted onto a PVDF membrane, using a semi-dry Trans-Blot Turbo Transfer System and a ready-to-use preassembled Trans-Blot Turbo Mini PVDF Transfer Pack at 2.5 mA, 25 V for 10 min in Towbin buffer \[25 mM Tris, 192 mM glycine, pH 8.3 at 25 °C\], with 20% methanol and 0.02% SDS. The membrane was blocked for 2 h 4 °C in TBS-T buffer \[50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.6 at 25 °C\] with 3% skimmed milk. The membrane was then incubated with conjugated anti-His-HRP antibodies diluted 1:2000 in TBS-T buffer with 3% skimmed milk for 1 h at 30 °C. The membrane was washed three times with TBS-T buffer and the specific protein was visualized by adding a DAB solution.

2.6. Statistical analysis {#sec2.6}
-------------------------

Where statistical analyses were perfomed, data are given as mean values ± standard error of the mean (SEM). The number of independent experiments is indicated in the Figure legends as n. Statistical comparisons were performed with STATISTICA (StatSoft, Krakow, Poland), the Mann-Whitney *U* Test was used and P values are indicated as \*p \< 0.05.

2.7. Evaluation of the autoligation efficiancy {#sec2.7}
----------------------------------------------

The autoligation of DNA fragments (encoding either the 7aa HBV epitope monomer or pentamer) was performed as described by Skowron et al., 2020 \[[@bib1]\]. The autoligation products were separated using polyacrylamide or agarose gel electrophoresis. Polyacrylamide and agarose gels were prepared in 1 × Tris-Borate-EDTA (TBE) buffer. The DNA bands were visualized after staining with Sybr Green I using a 312-nm UV transilluminator and photographed with a SYBR Green gel stain photographic filter.

The autoligation reaction effectiveness was determined by densitometry analysis of the selected DNA bands. The intensities of DNA bands, corresponding to the 7aa HBV epitope monomer or pentamer were measured using UnScan-It software and the persentage of the non-ligated DNA substrate was calculated for each ligation time tested. Autoligation experiments were performed in triplicate.
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